Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	5.34	2.4	5.37	3.13	3.82	7.4
Cash & Short-Term Investments	5.34	2.4	5.37	3.13	3.82	7.4
Cash Growth	48.07%	-55.36%	71.80%	-18.12%	-48.35%	75.26%
Accounts Receivable	3.18	2.53	2.23	2.9	2.57	2.41
Other Receivables	-	0.09	0.21	0.26	0.24	0.22
Receivables	3.18	2.61	2.44	3.16	2.81	2.63
Inventory	3.79	3.65	2.92	2.72	2.86	2.66
Prepaid Expenses	3.96	3.44	1.92	3.54	4.31	3.75
Total Current Assets	16.27	12.1	12.65	12.55	13.8	16.43
Property, Plant & Equipment	0.87	0.91	0.31	0.65	0.91	0.88
Long-Term Deferred Tax Assets	0.91	0.88	0.59	1.15	0.95	0.83
Other Long-Term Assets	0.07	0.06	0.15	0.4	0.58	0.71
Total Assets	18.11	13.96	13.69	14.74	16.23	18.85

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	2.19	1.92	0.95	0.61	0.84	1.64
Accrued Expenses	2.67	1.72	1.74	1.42	1.46	1.06
Short-Term Debt	0.14	0.22	0.22	0.32	0.43	0.69
Current Portion of Long-Term Debt	-	-	-	-	-	0.12
Current Portion of Leases	0.16	0.15	0.06	0.2	0.26	0.25
Current Unearned Revenue	0.28	0.28	0.64	0.48	0.16	1.28
Other Current Liabilities	-	0.53	0.49	0.69	0.57	0.78
Total Current Liabilities	5.45	4.83	4.1	3.72	3.72	5.82
Long-Term Leases	0.44	0.47	0.03	0.09	0.16	0.31
Long-Term Unearned Revenue	-	-	0.02	0.09	0.14	0.18
Other Long-Term Liabilities	5.63	5.56	5.14	4.71	4.24	3.84
Total Liabilities	11.51	10.87	9.28	8.6	8.25	10.15

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	-	-	-	0.01	0
Additional Paid-In Capital	210.91	207.32	206.59	203.21	200.9	197.37
Retained Earnings	-201.31	-200.98	-197.81	-194.35	-189.51	-184.36
Comprehensive Income & Other	-3.01	-3.24	-4.38	-2.72	-3.42	-4.31
Shareholders' Equity	6.59	3.1	4.41	6.14	7.98	8.7
Total Liabilities & Equity	18.11	13.96	13.69	14.74	16.23	18.85

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	0.74	0.84	0.31	0.61	0.85	1.37
Net Cash (Debt)	4.6	1.56	5.07	2.52	2.97	6.03
Net Cash Growth	56.96%	-69.28%	101.15%	-15.18%	-50.72%	290.23%
Net Cash Per Share	2.06	0.92	4.08	5.54	17.51	45.45
Filing Date Shares Outstanding	4.79	4.79	1.64	0.94	0.25	0.16
Total Common Shares Outstanding	4.79	1.8	1.63	0.78	0.25	0.16
Working Capital	10.82	7.27	8.55	8.83	10.08	10.61
Book Value Per Share	1.38	1.72	2.70	7.86	32.34	56.09
Tangible Book Value	6.59	3.1	4.41	6.14	7.98	8.7
Tangible Book Value Per Share	1.38	1.72	2.70	7.86	32.34	56.09
Machinery	-	2.23	1.81	2.14	1.95	1.53
Leasehold Improvements	-	0.56	0.49	0.61	0.55	0.5

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 16, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error